Bristol-Myers Squibb Co vs Dolby Laboratories, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.41 (market cap $129.94B), while Dolby Laboratories, Inc. trades at $60.91 (market cap $5.75B). The key difference: Bristol-Myers Squibb Co is far larger — about 22.6× Dolby Laboratories, Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | DLB | |
|---|---|---|
Market Cap | $129.94B | $5.75B |
Sector | Health | Industrials |
52-Week High | $65.89 | $75.62 |
52-Week Low | $42.60 | $48.51 |
Enterprise Value | $163.92B | $5.12B |
Dividend Yield | 3.96% | 2.35% |
Trailing returns across standard periods
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →